Gout is the most common type of inflammatory arthritis in adults, and it typically occurs in men over the age of 50. When gout presents in younger patients or in women, this should warrant consideration of secondary causes. We describe an unusual genetic cause of tophaceous gout in a young, premenopausal woman. Case Report In…
When rheumatologists think about rheumatoid arthritis (RA), they are apt to picture the synovium, contemplate such antibodies as rheumatoid factor and those to citrullinated proteins, and consider how this interplay of factors manifests in disease. What is not as commonly discussed is the role the autonomic nervous system plays in the pathogenesis and symptomatology of…
One thing that became clear very quickly this past year was that the COVID-19 pandemic would change the way we deliver care to patients. What has not changed amid an evolving healthcare landscape is our driving focus to ensure our patients’ access to rheumatology care and the availability of state-of-the-art treatments. We know you share…
According to a recent cohort study, patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab therapy experience more severe COVID-19. Researchers also found an association between rituximab use and prolonged hospital stays.
In a study of patients with systemic autoimmune rheumatic diseases (ARDs) and matched comparators with COVID-19 but without systemic ARDs, D’Silva et al. found COVID-19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission and more than matched comparators.
Fear of injection decreased when patients with RA switched from self-administering a treatment biosimilar to etanercept in a prefilled syringe to an injector pen, according to a small observational study.
On May 20, ACR representatives held more than 100 video meetings with Congressional leaders about the need to reform step therapy and alleviate pediatric workforce shortages. You can still add your voice by asking your members of Congress to support the Safe Step Act and fund the Pediatric Subspecialty Loan Repayment Program.
Patients with autoimmune diseases, such as spondyloarthritis, are at risk of developing inflammatory bowel disease. Here are considerations for its management and treatment.
As the U.S. and other patents for branded denosumab products get closer to expiring, drug manufacturers are initiating clinical trials for more affordable, biosimilar versions of the treatment.
Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.